芪苈强心胶囊对缺血性心肌病心力衰竭患者左室重构、心功能、N-末端脑钠肽前体及肌钙蛋白I的影响

目的观察芪苈强心胶囊对缺血性心肌病心力衰竭患者左室重构、心功能、N-末端脑钠肽前体(NTproBNP)及肌钙蛋白I(cTnI)的影响。方法将60例心力衰竭患者随机分为治疗组与对照组各30例,均常规予以血管紧张素转换酶抑制剂或血管紧张素II受体拮抗剂、β受体阻滞剂、利尿剂等治疗,治疗组加用芪苈强心胶囊。治疗6个月后对比观察2组临床症状、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)、每分钟输出量(CO)、NT-pro BNP、cTnI等的变化情况。结果治疗组临床总有效率明显高于对照组,差异有统计学意义(93.34%vs.80.00%,P<0.05)。与治疗前比较,2组治疗后NT-proBNP、cTnI、LVEDD均明显降低,LVEF、CO均明显增加,差异有统计学意义(P<0.05或P<0.01),而且治疗组治疗后6个月与对照组同期比较NT-proBNP、cTnI水平下降更明显,LVEDD、LVESD、LVEF、CO改善更明显,差异有统计学意义(P<0.05)。治疗组住院时间、再住院率均低于对照组(P<0.05)。结论在心力衰竭常规治疗的基础之上加用芪苈强心胶囊能够降低NT-proBNP、cTnI的水平,逆转左室重构,改善心功能,疗效明显。

The effect of Qiliqiangxin capsules on left ventricular remodeling,heart function,N-terminal pro-brain natriuretic peptide and cardiac troponin I in patients with ischemic heart disease and heart failure

Objective To investigate the effect of Qiliqiangxin capsules on left ventricular remodeling, cardiac func- tion, N-terminal pro brain natriuretic peptide （NT-proBNP） and cardiac troponin I （cTnI） in patients with isehemic cardio- myopathy and heart failure. Methods Sixty cases of heart failure patients were rartdomly divided into treatment group and control group with 30 cases in each group, they were given angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, beta blockers, diuretics, the treatment group added Qiliqiangxin capsules. 6 months after treatment, clinical symptoms, left ventricular end-diastolic diameter （LVEDD）, Left ventricular end-systolic diameter（LVESD）, left ventricular ejection fraction （LVEF）, output per minute （CO）, changes of NT-proBNP, cTnI were observed and compared between the 2 groups. Results Total effective rate in the treatment group was significantly higher than the control group, the difference was statistically significant （93.. 33% vs. 80.00%, P 〈 0.05）. Compared with before treatment, the 2 groups after treat- ment, NT-proBNP, cTnI, LVEDD were decreased, LVEF, CO were increased significantly, the difference was statistically significant （ P 〈0.05 or P 〈0.01 ） , and 6 months after treatment, the treatment group~ NT-proBNP, cTnI drop obviously, LVEDD, LVESD, LVEF, CO improved obviously compared to the same period in the control group, the difference was staffs- tically significant （ P 〈 0.05 ）. The treatment group hospital stay, readmission rates were lower than the control group （ P 〈 O. 05 ）. Conclusion For heart failure, on the basis of routine treatment, added Qiliqiangxin capsules could reduce the levels of cTnl, NT-proBNP, reverse left ventricular remodeling, and improve the heart function.